Parklaan 46 B-2300 Turnhout, Belgium   +32 14 720275


Project Introduction

DADA Consultancy BV is a premier and independent pharmaceutical consulting agency from the Netherlands. DADA has established its sound reputation as a highly specialized, reliable partner of international pharmaceutical companies, offering a full range of tailor-made developmental and international regulatory affairs and pharmacovigilance services in the fields of human and veterinary medicinal products, nutraceuticals, herbal medicinal products, medical devices and cosmetics, covering all European Member States and related regulated markets.

After a first prospection visit to China, DADA discovered the huge potential of the Chinese pharmaceutical industry, including state-of-the-art GMP manufacturing facilities. In recent years China’s pharmaceutical industry is moving up the value chain and is building a lot of additional capacity for finished dosage forms, also for exports to the USA and to Europe.

Since 2012 Dada has been targeting Chinese pharmaceutical companies that want to register and sell their products on the European market. Several visits to pharmaceutical exhibitions and companies have in the meantime been organised, leading to some successful projects.



Involvement of Horsten International

Horsten's professional team, with decades of experience in the pharmaceutical industy in China, was instrumental in introducing and negotiating the very first Chinese project of DADA in 2012.

Ever since then Horsten and DADA have been working together successfully in the search for additional customers in China, project management, visits and participations to exhibitions in China and prospection visits to China. Furthermore, Horsten has been assisting DADA in the communication with its Chinese customers and several partnerships are being set up to share competences and further attract Chinese pharmaceutical companies to develop its business in Europe.

Horsten and Dada work together successfully for the registration, marketing authorization and launching of their Chinese customers' pharmaceutical products on the European market.